| Type III interferons disrupt the lung epithelial barrier upon viral recognition A Broggi, S Ghosh, B Sposito, R Spreafico, F Balzarini, A Lo Cascio, ... Science 369 (6504), 706-712, 2020 | 374 | 2020 |
| The interferon landscape along the respiratory tract impacts the severity of COVID-19 B Sposito, A Broggi, L Pandolfi, S Crotta, N Clementi, R Ferrarese, S Sisti, ... Cell 184 (19), 4953-4968. e16, 2021 | 222 | 2021 |
| Viral respiratory pathogens and lung injury N Clementi, S Ghosh, M De Santis, M Castelli, E Criscuolo, I Zanoni, ... Clinical microbiology reviews 34 (3), 10.1128/cmr. 00103-20, 2021 | 125 | 2021 |
| Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules M Stravalaci, I Pagani, EM Paraboschi, M Pedotti, A Doni, F Scavello, ... Nature Immunology, 2022 | 121 | 2022 |
| Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro N Clementi, C Scagnolari, A D’Amore, F Palombi, E Criscuolo, F Frasca, ... Pharmacological research 163, 105255, 2021 | 121 | 2021 |
| Alternative methods of vaccine delivery: an overview of edible and intradermal vaccines E Criscuolo, V Caputo, RA Diotti, GA Sautto, GA Kirchenbaum, ... Journal of immunology research 2019 (1), 8303648, 2019 | 120 | 2019 |
| Comparative evaluation of the Bruker Biotyper and Vitek MS matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry systems for identification … N Mancini, E De Carolis, L Infurnari, A Vella, N Clementi, L Vaccaro, ... Journal of clinical microbiology 51 (7), 2453-2457, 2013 | 113 | 2013 |
| Potential impact of a microarray-based nucleic acid assay for rapid detection of Gram-negative bacteria and resistance markers in positive blood cultures N Mancini, L Infurnari, N Ghidoli, G Valzano, N Clementi, R Burioni, ... Journal of clinical microbiology 52 (4), 1242-1245, 2014 | 95 | 2014 |
| Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein GA Sautto, K Wisskirchen, N Clementi, M Castelli, RA Diotti, J Graf, ... Gut 65 (3), 512-523, 2016 | 93 | 2016 |
| Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials E Criscuolo, RA Diotti, R Ferrarese, C Alippi, G Viscardi, C Signorelli, ... Emerging Microbes & Infections 10 (1), 206-209, 2021 | 92 | 2021 |
| Interferon-β-1a inhibition of severe acute respiratory syndrome–coronavirus 2 in vitro when administered after virus infection N Clementi, R Ferrarese, E Criscuolo, RA Diotti, M Castelli, C Scagnolari, ... The Journal of infectious diseases 222 (5), 722-725, 2020 | 80 | 2020 |
| Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection M Severa, RA Diotti, MP Etna, F Rizzo, S Fiore, D Ricci, M Iannetta, ... bioRxiv, 2021 | 79 | 2021 |
| A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes N Clementi, D De Marco, N Mancini, L Solforosi, GJ Moreno, ... PloS one 6 (12), e28001, 2011 | 79 | 2011 |
| Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes N Mancini, RA Diotti, M Perotti, G Sautto, N Clementi, G Nitti, AH Patel, ... PloS one 4 (12), e8254, 2009 | 78 | 2009 |
| Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogens N Clementi, N Mancini, L Solforosi, M Castelli, M Clementi, R Burioni International Journal of Molecular Sciences 13 (7), 8273-8292, 2012 | 72 | 2012 |
| Molecular tracing of SARS-CoV-2 in Italy in the first three months of the epidemic A Lai, A Bergna, S Caucci, N Clementi, I Vicenti, F Dragoni, AM Cattelan, ... Viruses 12 (8), 798, 2020 | 71 | 2020 |
| COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models A Conforti, E Marra, F Palombo, G Roscilli, M Ravà, V Fumagalli, A Muzi, ... Molecular Therapy 30 (1), 311-326, 2022 | 66 | 2022 |
| A potential role for monoclonal antibodies in prophylactic and therapeutic treatment of influenza N Mancini, L Solforosi, N Clementi, D De Marco, M Clementi, R Burioni Antiviral research 92 (1), 15-26, 2011 | 66 | 2011 |
| A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses D De Marco, N Clementi, N Mancini, L Solforosi, GJ Moreno, X Sun, ... PLoS One 7 (4), e34415, 2012 | 65 | 2012 |
| Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV) R Burioni, F Canducci, N Mancini, N Clementi, M Sassi, D De Marco, ... Virology 399 (1), 144-152, 2010 | 65 | 2010 |
Elena CriscuoloLaboratory of Microbiology and Virology, Vita-Salute San Raffaele UniversityVerified email at hsr.it
